⌘K

AVR

NASDAQ

Anteris Technologies Global Corp.

SectorHealth CareIndustryIndustrial SpecialtiesIPO2024

News25/Ratings6

News · 26 weeks62-86%

2025-10-262026-04-19

Mix1690d

Other6(38%)
SEC Filings5(31%)
Insider3(19%)
Analyst2(13%)

Latest news

25 items

6hSEC
Anteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
36dSEC
SEC Form 424B3 filed by Anteris Technologies Global Corp.
424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
38dSEC
SEC Form EFFECT filed by Anteris Technologies Global Corp.
EFFECT - Anteris Technologies Global Corp. (0002011514) (Filer)
42dANALYST
Cantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price target
Cantor Fitzgerald resumed coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $15.00
43dANALYST
Wells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price target
Wells Fargo initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $16.00
44dSEC
SEC Form POS AM filed by Anteris Technologies Global Corp.
POS AM - Anteris Technologies Global Corp. (0002011514) (Filer)
48dINSIDER
SEC Form 4 filed by Chief Financial Officer Mcdonnell Matthew
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
51dSEC
Anteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
56dPR
Anteris Reports 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve p
56dSEC
SEC Form 10-K filed by Anteris Technologies Global Corp.
10-K - Anteris Technologies Global Corp. (0002011514) (Filer)
59dPR
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference. The details of each conference and how to access them are as follows: TD Cowen 46th Annual Healthcare Conference Date:Monday, March 2nd, 2026 (US time)Format:Fireside chat wi
69dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.
SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
73dINSIDER
Large owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
77dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.
SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
84dSEC
SEC Form SCHEDULE 13D filed by Anteris Technologies Global Corp.
SCHEDULE 13D - Anteris Technologies Global Corp. (0002011514) (Subject)
84dINSIDER
New insider Medtronic Plc claimed ownership of 15,652,173 shares (SEC Form 3)
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
91dSEC
SEC Form 424B3 filed by Anteris Technologies Global Corp.
424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
91dSEC
Anteris Technologies Global Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
91dPR
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ:MDT) (Medtronic), the world's largest medical technology company. The investment closed immediately following Anteris' underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advan
91dPR
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the "Offering") of 40,000,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares from the Company (the "Shares"). The Shares were sold at a public offering price of $5.75 per share. In addition, Anteris today announced the closing of its previously anno
91dSEC
Anteris Technologies Global Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
92dSEC
SEC Form 424B5 filed by Anteris Technologies Global Corp.
424B5 - Anteris Technologies Global Corp. (0002011514) (Filer)
92dSEC
SEC Form FWP filed by Anteris Technologies Global Corp.
FWP - Anteris Technologies Global Corp. (0002011514) (Subject)
92dPR
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the "Offering") of 34,782,609 shares of its common stock (the "Shares"). The Shares are being sold at a public offering price of $5.75 per share. The gross proceeds to the Company from the Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $200 million.
93dSEC
SEC Form FWP filed by Anteris Technologies Global Corp.
FWP - Anteris Technologies Global Corp. (0002011514) (Subject)